Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Hyloris Pharmaceuticals SA ( (DE:52U) ) is now available.
Hyloris Pharmaceuticals has signed an exclusive licensing agreement to develop a ready-to-use intravenous formulation of pantoprazole, a drug used to treat gastric acid-related conditions. This new formulation simplifies administration, reduces preparation time, and improves cost efficiency, potentially capturing a significant market share and enhancing patient care globally.
More about Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company focused on addressing unmet medical needs by reinventing existing medications. The company is committed to advancing healthcare delivery through innovative solutions.
YTD Price Performance: -22.97%
Average Trading Volume: 299
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €165.2M
Find detailed analytics on 52U stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money